TY - JOUR
T1 - CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications
AU - Franch-Expósito, Sebastià
AU - Bassaganyas, Laia
AU - Vila-Casadesús, Maria
AU - Hernández-Illán, Eva
AU - Esteban-Fabró, Roger
AU - Díaz-Gay, Marcos
AU - Lozano, Juan José
AU - Castells, Antoni
AU - Llovet, Josep M.
AU - Castellví-Bel, Sergi
AU - Camps, Jordi
N1 - Funding Information:
This work has been supported by the European Commission [PCIG11-GA-2012-321937]; the Instituto de Salud Carlos III and co-funded by the European Regional Development Fund (ERDF) [CP13/00160, PI14/00783, PI17/01304, PI17/00878]; the CIBEREHD program; the CERCA Program (Generalitat de Catalunya); the Ag?ncia de Gesti? d'Ajuts Universitaris i de Recerca, Generalitat de Catalunya [2017 SGR 1035, 2017 SGR 21, 2017 SGR 653]; PERIS Generalitat de Catalunya [SLT002/16/00398]; Fundaci?n Cient?fica de la Asociaci?n Espa?ola Contra el C?ncer [GCB13131592 CAST]; CIBEREHD contract to SF-E; Ag?ncia de Gesti? d'Ajuts Universitaris i de Recerca-AGAUR-from Generalitat de Catalunya [2016BP00161] to LB and [2018FI B1_00213] to MD-G; Spanish National Health Institute FPI grant [BES-2017-081286] to RE-F. CIBEREHD is funded by the Instituto de Salud Carlos III. This article is based upon work from COST Action [CA17118], supported by COST (European Cooperation in Science and Technology). JML is supported by the European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273-2), U.S. Department of Defense (CA150272P3), National Cancer Institute (P30-CA196521), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390) and Generalitat de Catalunya/AGAUR (SGR-1162 and SGR-1358).
Funding Information:
This work has been supported by the European Commission [PCIG11-GA-2012-321937]; the Instituto de Salud Carlos III and co-funded by the European Regional Development Fund (ERDF) [CP13/00160, PI14/00783, PI17/01304, PI17/00878]; the CIBEREHD program; the CERCA Program (Generalitat de Catalunya); the Agència de Gestió d'Ajuts Universitaris i de Recerca, Generalitat de Catalunya [2017 SGR 1035, 2017 SGR 21, 2017 SGR 653]; PERIS Generalitat de Catalunya [SLT002/16/00398]; Fundación Científica de la Asociación Española Contra el Cáncer [GCB13131592CAST]; CIBEREHD contract to SF-E; Agència de Gestió d'Ajuts Universitaris i de Recerca -AGAUR-from Generalitat de Catalunya [2016BP00161] to LB and [2018FI B1_00213] to MD-G; Spanish National Health Institute FPI grant [BES-2017-081286] to RE-F. CIBEREHD is funded by the Instituto de Salud Carlos III. This article is based upon work from COST Action [CA17118], supported by COST (European Cooperation in Science and Technology). JML is supported by the European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273-2), U.S. Department of Defense (CA150272P3), National Cancer Institute (P30-CA196521), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390) and Generalitat de Catalunya/AGAUR (SGR-1162 and SGR-1358).
Publisher Copyright:
© 2019, Galenos. All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma, and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at https://tools.idibaps.org/CNApp/.
AB - Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma, and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at https://tools.idibaps.org/CNApp/.
KW - CNA scores
KW - Cancer genomics
KW - Colorectal cancer
KW - Copy number alterations
KW - Hepatocellular carcinoma
KW - Pan-cancer
KW - Shiny app
UR - http://www.scopus.com/inward/record.url?scp=85079172135&partnerID=8YFLogxK
U2 - 10.7554/eLife.50267
DO - 10.7554/eLife.50267
M3 - Article
C2 - 31939734
AN - SCOPUS:85079172135
SN - 2050-084X
VL - 9
JO - eLife
JF - eLife
M1 - e50267
ER -